FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 0E 0		FIOLAL	OLA/AI

OMB A	PPROVAL
OMB Number:	3235-0287

0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Estimated average burden hours per response: Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	Check this box if no longer subject to
$\neg$	Section 16. Form 4 or Form 5
_	obligations may continue. See
	Instruction 1(b).

							( )				1								
1. Name and Address of Reporting Person*  COZADD BRUCE C					2. Issuer Name and Ticker or Trading Symbol  Jazz Pharmaceuticals plc [ JAZZ ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
<u>COZADD BRUCE C</u>						Succession of the succession o								X	Direc	ctor	10%	Owner	
(Last) (First) (Middle)														X	Officer (give title below)		Other (specify below)		
C/O JAZZ PHARMACEUTICALS PLC					3. Date of Earliest Transaction (Month/Day/Year) 09/10/2013								Chairman and CEO						
CONNAUGHT HOUSE, 1 BURLINGTON RD, FL. 4																			
					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable					
(Street)						Line								X Form filed by One Reporting Person					
DUBLIN	14 L2													21	Form	n filed by Mor	e than One Re		
(City)	(St	ate) (	Zip)												Pers	on			
(- 3)				n Doriv	otivo	S00	uritio	- A -	au irod	l Die	sposed o	forF	Popofici	ally C	)woo				
			e i - ivo			_			·	ı, Di	_	•					<u> </u>		
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day				Execution Date,		Date,	3. Transa Code ( 8)					and 5) Secur Benef Owne		cially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) o	Price	- 1		ted action(s) 3 and 4)		(Instr. 4)	
Ordinary	Shares			09/10/2	:013		<b>S</b> <sup>(1)</sup>		5,000	D	\$87.5	<b>59</b> <sup>(2)</sup>	62	29,647	D				
		Та	ıble II -								osed of, convertib				ned				
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security			3A. Dee Execution if any (Month/I						6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Shares						

## **Explanation of Responses:**

- 1. The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$87.27 to \$87.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein

## Remarks:

/s/ Larissa Schwartz as attorney 09/10/2013 in fact for Bruce Cozadd

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.